Bond Cliff

Main Menu

  • Home
  • Economic integration
  • Price index
  • Covariance
  • Labor augmenting
  • Fund

Bond Cliff

Header Banner

Bond Cliff

  • Home
  • Economic integration
  • Price index
  • Covariance
  • Labor augmenting
  • Fund
Covariance
Home›Covariance›Effects of liraglutide on visceral and ectopic fat in overweight and obese adults at high cardiovascular risk: a randomized, double-blind, placebo-controlled clinical trial

Effects of liraglutide on visceral and ectopic fat in overweight and obese adults at high cardiovascular risk: a randomized, double-blind, placebo-controlled clinical trial

By Susan Weiner
August 3, 2021
0
0


  • 1.
    • Powell-WileyTM
    • Pear tree P
    • Burke LE
    • et al.

    Obesity and Cardiovascular Disease: A Scientific Statement from the American Heart Association.

    Circulation. 2021; 143: e984-1010

  • 2.
    • Hales CM
    • CD Fryer
    • Carroll MD
    • Freedman DS
    • Ogden CL

    Trends in obesity and the prevalence of severe obesity among U.S. youth and adults by sex and age, 2007-2008 to 2015-2016.

    JAMA. 2018; 319: 1723-1725

  • 3.
    • Hales CM
    • Carroll MD
    • CD Fryer
    • Ogden CL

    Prevalence of obesity and severe obesity in adults: United States, 2017-2018.

    NCHS Data Sheet. 2020; 360: 1-8

  • 4.

    Fifty Years of Behavioral / Lifestyle Interventions for Overweight and Obesity: Where Are We and Where Are We Going ?.

    Obesity (Silver Spring). 2017; 25: 1867-1875

  • 5.
    • Montesi L
    • El Ghoch M
    • Brodosi L
    • Calugi S
    • Marchesini G
    • Grave R slab

    Maintaining long-term weight loss for obesity: a multidisciplinary approach.

    Diabetes Metab Syndr Obes. 2016; 9: 37-46

  • 6.
    • RR wing
    • Bolin P
    • Brancati FL
    • et al.

    Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

    N Engl J Med. 2013; 369: 145-154

  • 7.
    • Neeland IJ
    • Turer AT
    • Ayers CR
    • et al.

    Dysfunctional adiposity and risk of prediabetes and type 2 diabetes in obese adults.

    JAMA. 2012; 308: 1150-1159

  • 8.
    • Neeland IJ
    • Turer AT
    • Ayers CR
    • et al.

    Distribution of body fat and cardiovascular disease in obese adults.

    J Am Coll Cardiol. 2015 ; 65: 2150-2151

  • 9.
    • Neeland IJ
    • Ayers CR
    • Rohatgi AK
    • et al.

    Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.

    Obesity (Silver Spring). 2013; 21: E439-E447

  • ten.
    • CS Fox
    • Massaro JM
    • Hoffmann U
    • et al.

    Visceral and subcutaneous fatty tissue compartments of the abdomen: association with metabolic risk factors in the Framingham Heart Study.

    Circulation. 2007; 116: 39-48

  • 11.
    • Liu J
    • CS Fox
    • Hickson DA
    • et al.

    Impact of abdominal, visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study.

    J Clin Endocrinol Metab. 2010; 95: 5419-5426

  • 12.
    • Boyko EJ
    • Fujimoto WY
    • Leonetti DL
    • Newell-Morris L

    Visceral adiposity and the risk of type 2 diabetes: a prospective study in Japanese Americans.

    Diabetic treatments. 2000; 23: 465-471

  • 13.
    • Khera R
    • Mourad MH
    • Chandar AK
    • et al.

    Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis.

    JAMA. 2016; 315: 2424-2434

  • 14.
    • Jensen MD
    • Ryan dh
    • CM Apovian
    • et al.

    2013 AHA / ACC / TOS Guidelines for the Management of Overweight and Obesity in Adults: Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and The Obesity Society.

    Circulation. 2014 ; 129: S102-S138

  • 15.
    • CM Apovian
    • Aronne LJ
    • Bessesen DH
    • et al.

    Pharmacological management of obesity: clinical practice guide from the Endocrine Society.

    J Clin Endocrinol Metab. 2015 ; 100: 342-362

  • 16.
    • Rao S
    • Pandey A
    • Garg S
    • et al.

    Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials.

    Mayo Clin Proc. 2019; 94: 211-224

  • 17.
    • Bizino MB
    • Jazet IM
    • by Heer P
    • et al.

    Randomized, placebo-controlled trial of liraglutide on magnetic resonance parameters in people with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.

    Diabetology. 2020; 63: 65-74

  • 18.
    • van Eyk HJ
    • Païman EHM
    • Bizino MB
    • et al.

    A randomized, double-blind, placebo-controlled trial to evaluate the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetic patients.

    Cardiovascular Diabetol. 2019; 18: 87

  • 19.
    • Ishii S
    • Nagai Y
    • Sada Y
    • et al.

    Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series.

    J Clin Med Res. 2019; 11: 219-224

  • 20.
    • Mehta A
    • Marso SP
    • Neeland IJ

    Liraglutide for weight management: a critical review of the evidence.

    Obes Sci Pract. 2017; 3: 3-14

  • 21.
    • Pi-Sunyer X
    • Astrup A
    • Fujioka K
    • et al.

    A randomized controlled trial of 3.0 mg of liraglutide in weight management.

    N Engl J Med. 2015 ; 373: 11-22

  • 22.
    • Davies MJ
    • Bergenstal R
    • Bode B
    • et al.

    Effectiveness of liraglutide for weight loss in patients with type 2 diabetes: the randomized clinical trial in diabetes SCALE.

    JAMA. 2015 ; 314: 687-699

  • 23.
    • AT Wadden
    • Hollander P
    • Klein S
    • et al.

    Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the randomized SCALE Maintenance study.

    Int J Obes. 2013; 37: 1443-1451

  • 24.
    • Marso SP
    • Daniels GH
    • Brown-Frandsen K
    • et al.

    Liraglutide and cardiovascular results in type 2 diabetes.

    N Engl J Med. 2016; 375: 311-322

  • 25.
    • JB Bus
    • SC bath
    • Mann JFE
    • et al.

    Reduction of cardiovascular risk with liraglutide: an exploratory mediating analysis of the LEADER trial.

    Diabetic treatments. 2020; 43: 1546-1552

  • 26.
    • Astrup A
    • Carraro R
    • Thinner N
    • et al.

    Safety, tolerance and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide.

    Int J Obes. 2012; 36: 843-854

  • 27.

    Saxenda from Novo Nordisk remains the best obesity treatment in the world.

  • 28.
    • Grundy SM
    • Cleeman ji
    • Daniels SR
    • et al.

    Diagnosis and management of metabolic syndrome: a scientific statement from the American Heart Association / National Heart, Lung, and Blood Institute.

    Circulation. 2005; 112: 2735-2752

  • 29.

    Human energy needs: report of a joint FAO / WHO / UNU expert consultation.

    Nutr Bull food. 2005; 26: 166

  • 30.
    • J west
    • Dahlqvist Leinhard O
    • Romu T
    • et al.

    Feasibility of MRI-based analysis of body composition in large-scale population studies.

    PLoS One. 2016; 11e0163332

  • 31.
    • Borga M
    • Thomas EL
    • Romu T
    • et al.

    Validation of a rapid method for quantifying intra-abdominal and subcutaneous adipose tissue for large-scale human studies.

    Biomed NMR. 2015 ; 28: 1747-1753

  • 32.
    • Karlsson A
    • Rosander J
    • Romu T
    • et al.

    Automatic and quantitative evaluation of regional muscle volume by multi-atlas segmentation using whole body water-fat MRI.

    J Magn Reson Imaging. 2015 ; 41: 1558-1569

  • 33.
    • J west
    • Romu T
    • Thorell S
    • et al.

    Accuracy of body composition measurements by MRI of postmenopausal women.

    PLoS One. 2018; 13e0192495

  • 34.
    • Borga M
    • Ahlgren A
    • Romu T
    • Widholm P
    • Dahlqvist Leinhard O
    • J west

    Reproducibility and repeatability of MRI body composition analysis.

    Magn Reson Med. 2020; 84: 3146-3156

  • 35.
    • Astrup A
    • Rössner S
    • Van Gaal L
    • et al.

    Effects of liraglutide in the treatment of obesity: randomized, double-blind, placebo-controlled study.

    Lancet. 2009; 374: 1606-1616

  • 36.
    • Santilli F
    • Simeone PG
    • Guagnano MT
    • et al.

    Effects of liraglutide on weight loss, fat distribution and β cell function in obese subjects with prediabetes or early type 2 diabetes.

    Diabetic treatments. 2017; 40: 1556-1564

  • 37.
    • Jendle J
    • Nauck MA
    • Matthews DR
    • et al.

    Weight loss with liraglutide, a human glucagon-like peptide-1 analogue given once daily for the treatment of type 2 diabetes as monotherapy or added to metformin, results primarily from reduction in adipose tissue.

    Diabetes Obes Metab. 2009; 11: 1163-1172

  • 38.
    • Wilding JPH
    • Batterham RL
    • Calanna S
    • et al.

    Semaglutide once a week in overweight or obese adults.

    N Engl J Med. 2021; 384: 989-1002

  • 39.
    • Shin J
    • Syme C
    • Wang D
    • et al.

    New genetic locus of visceral fat and systemic inflammation.

    J Clin Endocrinol Metab. 2019; 104: 3735-3742

  • 40.
    • Ridker PM
    • Everett BM
    • Thuren T
    • et al.

    Anti-inflammatory therapy with canakinumab for atherosclerotic disease.

    N Engl J Med. 2017; 377: 1119-1131

  • 41.
    • Nidorf SM
    • ATL Fiolet
    • Mosterd A
    • et al.

    Colchicine in patients with chronic coronary artery disease.

    N Engl J Med. 2020; 383: 1838-1847

  • 42.
    • Matikainen N
    • Söderlund S
    • Björnson E
    • et al.

    Liraglutide Treatment Improves Postprandial Lipid Metabolism and Cardiometabolic Risk Factors in Men With Well-Controlled Type 2 Diabetes: A Single-Center Randomized Controlled Study.

    Diabetes Obes Metab. 2019; 21: 84-94

  • 43.
    • Taher J
    • Baker C
    • Alvares D
    • Ijaz L
    • Hussein M
    • Adeli K

    GLP-2 deregulates hepatic lipoprotein metabolism, inducing hepatic steatosis and overproduction of VLDL in hamsters and male mice.

    Endocrinology. 2018; 159: 3340-3350

  • 44.
    • Hussein A
    • Ballantyne CM
    • Said A
    • Virani SS

    Triglycerides and risk reduction of ASCVD: recent perspectives and future directions.

    Curr Atheroscler Rep. 2020; 22: 25

  • 45.
    • Nielsen S
    • Guo Z
    • Johnson CM
    • Hensrud DD
    • Jensen MD

    Splanchnic lipolysis in human obesity.

    J Clin Invest. 2004 ; 113: 1582-1588

  • 46.

    Body fat distribution and cardiovascular disease risk: an update.

    Circulation. 2012; 126: 1301-1313

  • 47.
    • Anholm C
    • Kumarathurai P
    • Pedersen LR
    • et al.

    Liraglutide in combination with metformin may improve atherogenic lipid profile and decrease C-reactive protein level in statin-treated patients with newly diagnosed coronary heart disease and type 2 diabetes: a randomized trial.

    Atherosclerosis. 2019; 288: 60-66

  • 48.
    • Burhans MS
    • Balou N
    • Schmidt KA
    • et al.

    Impact of the analytical approach on the reliability of the MRI assessment of hepatic fat content.

    Curr Dev Nutr. 2020; 4nzaa171

  • 49.
    • Berkowitz RI
    • AT Wadden
    • Tershakovec AM
    • Cronquist JL

    Behavioral therapy and sibutramine for the treatment of obesity in adolescents: a randomized controlled trial.

    JAMA. 2003; 289: 1805-1812


  • Related posts:

    1. A Guide to Data Clustering Methods in Python
    2. Urban emissions, air quality and heat: CSU researchers receive more than $ 2.2 million
    3. Prototype radar will detect areas of increased greenhouse gas emissions in the Florida Everglades
    4. Cyclones have a positive effect on the ability of mangroves to fix carbon dioxide: study
    Tagslong termunited states

    Categories

    • Covariance
    • Economic integration
    • Fund
    • Labor augmenting
    • Price index
    • TERMS AND CONDITIONS
    • Privacy Policy